CRIAM

CRIAM specializes in portable, point-of-care in vitro diagnostic devices, focusing on blood testing. Their technology allows for accurate, on-the-spot blood analysis, assessing parameters such as blood type, nutrients, and diseases. This capability is particularly beneficial for emergency care and infectious disease control, as it provides rapid diagnostics outside traditional laboratory settings. The company operates on a B2B model, targeting hospitals, government institutes, and healthcare providers. Revenue is generated from the sale of hardware devices, consumable cartridges, and software-as-a-service (SaaS) algorithms. CRIAM is actively pursuing regulatory approvals, including FDA and CE marks, to expand its market reach internationally. Their team consists of experts in biochemistry, computer vision, and machine learning, which supports the development of their advanced diagnostic platform.

• Employees 6
• Founded 2016
• Annual Revenue $3000000
• Total Funding $2100000